Madabhavi I, et al. - Researchers sought to determine how imatinib influence pregnancy in patients with chronic myeloid leukemia (CML). They Data were collected. From January 1998 to December 2014, data of 104 patients who met inclusion criteria were assessed, and the results of 104 pregnancies—conceived by the participant or partner—while being on imatinib therapy for CML were reported. Of these, 58 patients were male and 46 were female. CML in the chronic phase, accelerated phase, or blast phase was reported in 83 patients, 20 patients, and one patient, respectively. Among 46 female patients, abortion was reported in 21 (spontaneous, n = 36.9; elective termination, n = 8.6%). In the female partners of male patients with CML, all outcomes were uneventful in the case of a full-term pregnancy. Among 46 female patients, full-term pregnancy outcomes were reported in 25. As per the analysis, there is no standard of care for the best treatment of CML in the case of pregnancy. Inclusion of interferon and/or leukapheresis as treatment options is expected. Normal pregnancies could be expected among patients even with the administration of imatinib at the risk of congenital anomalies, intervention for which can be done after birth.